|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4271164A
(en)
|
1979-04-16 |
1981-06-02 |
Warner-Lambert Company |
6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
|
|
HU196714B
(en)
|
1984-10-04 |
1989-01-30 |
Monsanto Co |
Process for producing non-aqueous composition comprising somatotropin
|
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
GB9420168D0
(en)
|
1994-10-06 |
1994-11-23 |
Boots Co Plc |
Therapeutic agents
|
|
AU6242096A
(en)
|
1995-06-27 |
1997-01-30 |
Takeda Chemical Industries Ltd. |
Method of producing sustained-release preparation
|
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
|
DE69730093T2
(de)
|
1996-10-31 |
2006-07-20 |
Takeda Pharmaceutical Co. Ltd. |
Zubereitung mit verzögerter Freisetzung
|
|
WO1998027980A2
(en)
|
1996-12-20 |
1998-07-02 |
Takeda Chemical Industries, Ltd. |
Method of producing a sustained-release preparation
|
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
|
CA2290509A1
(en)
|
1997-07-01 |
1999-01-14 |
Warner-Lambert Company |
2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
|
|
JP2910748B2
(ja)
|
1997-11-12 |
1999-06-23 |
日本電気株式会社 |
異質同軸部材の端面の球状加工装置及びその方法
|
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
|
HUP0105092A3
(en)
|
1999-01-13 |
2003-12-29 |
Warner Lambert Co |
1-heterocycle substituted diarylamines and medicaments containing them
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
SG2013013339A
(en)
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US20050202001A1
(en)
|
2002-04-24 |
2005-09-15 |
Han-Mo Koo |
Enhancement of human epidermal melanogenesis
|
|
CA2492112A1
(en)
|
2002-08-06 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
|
CA2546353A1
(en)
*
|
2003-11-19 |
2005-06-09 |
Array Biopharma Inc. |
Bicyclic inhibitors of mek and methods of use thereof
|
|
WO2006078287A2
(en)
|
2004-05-06 |
2006-07-27 |
Plexxikon, Inc. |
Pde4b inhibitors and uses therefor
|
|
AU2005252110B2
(en)
|
2004-06-11 |
2008-09-04 |
Shionogi & Co., Ltd. |
5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
|
|
US7674907B2
(en)
|
2004-07-23 |
2010-03-09 |
Amgen Inc. |
Furanopyridine derivatives and methods of use
|
|
MX2007004781A
(es)
*
|
2004-10-20 |
2007-05-11 |
Applied Research Systems |
Derivados de 3-arilamino piridina.
|
|
JP5710855B2
(ja)
|
2005-02-02 |
2015-04-30 |
ネクスジェニクス・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
神経線維腫の局所治療
|
|
CN102206216B
(zh)
|
2005-06-22 |
2014-11-12 |
普莱希科公司 |
作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
|
|
HRP20110498T1
(hr)
*
|
2005-10-07 |
2011-08-31 |
Exelixis |
Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
|
|
EP1966155A1
(en)
|
2005-12-21 |
2008-09-10 |
AstraZeneca AB |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
US7772233B2
(en)
|
2006-04-19 |
2010-08-10 |
Merck Serono, S.A. |
Arylamino N-heteroaryl compounds as MEK inhibitors
|
|
GB0616214D0
(en)
|
2006-08-15 |
2006-09-27 |
Ucb Sa |
Therapeutic Agents
|
|
CN101528231A
(zh)
|
2006-08-16 |
2009-09-09 |
埃克塞利希斯股份有限公司 |
在癌症的治疗中使用pi3k和mek调控剂
|
|
ES2528797T3
(es)
|
2006-08-21 |
2015-02-12 |
Genentech, Inc. |
Compuestos de aza-benzotiofenilo y métodos de uso
|
|
ES2376771T3
(es)
|
2006-08-21 |
2012-03-16 |
Genentech, Inc. |
Compuestos aza-benzofuranilo y métodos de utilización
|
|
RU2463038C2
(ru)
|
2006-10-17 |
2012-10-10 |
Нуво Рисерч Инк. |
Диклофенаковый гель
|
|
EP2089359A2
(en)
|
2006-10-31 |
2009-08-19 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
EP2099796B1
(en)
|
2006-11-30 |
2011-06-01 |
Genentech, Inc. |
Aza-indolyl compounds and methods of use
|
|
CL2008001373A1
(es)
|
2007-05-11 |
2008-11-21 |
Bayer Schering Pharma Ag |
Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
|
|
WO2008148034A1
(en)
|
2007-05-25 |
2008-12-04 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
AU2008343065B2
(en)
|
2007-12-19 |
2012-04-05 |
Genentech, Inc. |
5-anilinoimidazopyridines and methods of use
|
|
NZ586575A
(en)
|
2007-12-21 |
2012-03-30 |
Genentech Inc |
Azaindolizines and methods of use
|
|
WO2009093008A1
(en)
|
2008-01-21 |
2009-07-30 |
Ucb Pharma S.A. |
Thieno-pyridine derivatives as mek inhibitors
|
|
GB0801081D0
(en)
|
2008-01-21 |
2008-02-27 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB0801080D0
(en)
|
2008-01-21 |
2008-02-27 |
Ucb Pharma Sa |
Therapeutic agents
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
EP2440204B1
(en)
*
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
|
WO2012040636A2
(en)
|
2010-09-24 |
2012-03-29 |
The Broad Institute, Inc. |
Compounds and methods for treating diseases mediated by protease activated receptors
|
|
MX341471B
(es)
|
2010-11-05 |
2016-08-22 |
Hoffmann La Roche |
Uso de compuestos farmaceuticos activos para el tratamiento de estados patologicos del sistema nervioso central.
|
|
WO2012099968A1
(en)
|
2011-01-19 |
2012-07-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating skin cancer associated diseases
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
JP5931187B2
(ja)
|
2011-06-17 |
2016-06-08 |
シェンヤン・シノケム・アグロケミカルズ・アールアンドディー・カンパニーリミテッドＳｈｅｎｙａｎｇ Ｓｉｎｏｃｈｅｍ Ａｇｒｏｃｈｅｍｉｃａｌｓ Ｒ＆Ｄ Ｃｏ．， Ｌｔｄ． |
置換シアノアニリン化合物、その調製法及び使用
|
|
WO2014179785A1
(en)
|
2013-05-03 |
2014-11-06 |
Inscent, Inc. |
Improved honeybee repellents and uses thereof
|
|
US9572828B2
(en)
|
2013-07-18 |
2017-02-21 |
The Board Of Regents Of The University Of Texas System |
Treatment for melanoma
|
|
CN105384738B
(zh)
|
2014-08-21 |
2017-08-29 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
CN105384754B
(zh)
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
EP3383912A4
(en)
|
2015-11-30 |
2019-11-06 |
Ignyta, Inc. |
TOPICAL FORMULATIONS
|
|
EP3301094A1
(en)
|
2016-09-30 |
2018-04-04 |
Mutabilis |
Heterocyclic compounds and their use in preventing or treating bacterial infections
|
|
DE102016225694A1
(de)
|
2016-12-21 |
2018-06-21 |
Robert Bosch Gmbh |
Verfahren zur Verstärkung der Bremskraft in einer elektronisch schlupfregelbaren Fahrzeugbremsanlage und elektronisch schlupfregelbare Fahrzeugbremsanlage
|
|
US11161845B2
(en)
|
2017-05-19 |
2021-11-02 |
Nflection Therapeutics, Inc. |
Pyrrolopyridine-aniline compounds for treatment of dermal disorders
|
|
MX2019013562A
(es)
|
2017-05-19 |
2020-08-03 |
Nflection Therapeutics Inc |
Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
|
|
WO2019139970A1
(en)
|
2018-01-09 |
2019-07-18 |
Duke University |
Topical administration of mek inhibiting agents for the treatment of skin disorders
|
|
CN113473986B
(zh)
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病萘啶酮苯胺化合物
|
|
WO2020106304A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Topical formulations
|
|
WO2020106307A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of birthmarks
|
|
AU2019383311B2
(en)
|
2018-11-20 |
2024-12-05 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
MA55143A
(fr)
|
2018-11-20 |
2021-09-29 |
H Lee Moffitt Cancer Center & Res Institute Inc |
Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
|
|
US12466818B2
(en)
|
2018-11-20 |
2025-11-11 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
US20240228480A1
(en)
|
2021-01-21 |
2024-07-11 |
Nflection Therapeutics, Inc. |
Processes for preparing pyrrolopyridine-aniline compounds
|
|
JP2024503892A
(ja)
|
2021-01-21 |
2024-01-29 |
エヌフレクション セラピューティクス インコーポレイテッド |
ピロロピリジン－アニリン化合物の結晶形
|